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Abstract
Viral reservoirs that persist in HIV-1 infected individuals on antiretroviral therapy (ART) are the major obstacle to viral
eradication. The identification and definition of viral reservoirs in patients on ART is needed in order to understand viral
persistence and achieve the goal of viral eradication. We examined whether analysis of episomal HIV-1 genomes provided
the means to characterize virus that persists during ART and whether it could reveal the virus that contributes to treatment
failure in patients on ART. For six individuals in which virus replication was highly suppressed for at least 20 months, proviral
and episomal genomes present just prior to rebound were phylogenetically compared to RNA genomes of rebounding virus
after therapy interruption. Episomal envelope sequences, but not proviral envelope sequences, were highly similar to
sequences in rebounding virus. Since episomes are products of recent infections, the phylogenetic relationships support the
conclusion that viral rebound originated from a cryptic viral reservoir. To evaluate whether the reservoir revealed by
episomal sequence analysis was of clinical relevance, we examined whether episomal sequences define a viral population
that contributes to virologic failure in individuals receiving the CCR5 antagonist, Vicriviroc. Episomal envelope sequences at
or near baseline predicted treatment failure due to the presence of X4 or D/M (dual/mixed) viral variants. In patients that did
not harbor X4 or D/M viruses, the basis for Vicriviroc treatment failure was indeterminate. Although these samples were
obtained from viremic patients, the assay would be applicable to a large percentage of aviremic patients, based on previous
studies. Summarily, the results support the use of episomal HIV-1 as an additional or alternative approach to traditional
assays to characterize virus that is maintained during long-term, suppressive ART.
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Introduction
Despite great advances in the treatment of HIV infection and
disease, therapeutic eradication of viral infection is currently not
possible. Individuals who respond well to ART and maximally
suppress virus replication based on standard assays, harbor viral
reservoirs that fuel a rapid rebound in viral replication upon
interruption of antiviral treatment. Although the biological
relevance of different reservoirs is subject to ongoing debate,
there is evidence to support the existence of at least two distinct
viral reservoirs that persist during effective, prolonged suppression
of HIV-1 replication. One is a latent reservoir that is comprised of
lymphocytes that were infected and subsequently reverted to a
quiescent state [1–3]. Reactivation of latently infected cells results
in viral gene expression and subsequent virion production. In
patients on HAART, this reservoir has been estimated to decay
with a half-life of greater than 44 months and is considered to be a
major obstacle to complete clearance of HIV-1 infection [4].
In addition to latently infected cells, there is mounting evidence
to support the existence of a reservoir of low-level ongoing
replication in patients on HAART. Evolution of viral envelope
sequences in the context of HAART has been documented for
HIV-1 infected patients [5,6] and detection of one and two long
terminal repeat circles (episomal HIV-1 cDNAs) in patients on
HAART indicates that new rounds of infection continue despite
highly suppressive treatment [7]. While short-term in vitro
experiments have suggested that 2-LTR circles are stable [8,9],
in vivo analysis has demonstrated their labile nature, which
supports the use of episomal HIV-1 cDNAs as a valid surrogate
marker of recently infected cells [10–12]. Perhaps the most
compelling evidence supporting the existence of a reservoir in
which low-level replication persists is derived from a study utilizing
a novel antiviral drug that targets the enzymatic activity of
integrase. In approximately 30% of patients on long-term
suppressive antiretroviral therapy, treatment with the integrase
inhibitor raltegravir led to a transient increase in 2-LTR circles
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results support the conclusion that, at least in some patients,
standard antiretroviral therapy is not fully suppressive and a
reservoir of cryptic replication fuels viral persistence.
Other groups have also focused on defining the effects of
therapy intensification on residual viremia using raltegravir,
yielding different conclusions [14–17]. As in the study by Buzo ´n
and colleagues, one group observed an increase in 2-LTR
episomal DNA levels in antiretroviral-experienced patients upon
therapy intensification [15]. While a third group did not observe
an increase in episomes in response to switching raltegravir for
enfuvirtide [14], the effects of raltegravir were assessed at week 24
and 48, which is likely to be well after the effects of intensification
occur. The remaining groups focused on measuring residual
viremia in order to gauge the effects of therapy intensification
using raltegravir [16,17]. Their main conclusion is that there is no
significant change in viremia in response to raltegravir treatment,
so the observed residual viremia is not due to ongoing cycles of
HIV-1 infection. It is unclear at this point what the residual
viremia represents. If it were derived from long-lived cells that
harbor integrated proviruses, one would not expect to observe an
effect upon therapy intensification with a new, potent antiviral.
While further work is necessary, episomal DNA may be a more
accurate marker of cryptic replication than residual viremia.
In patients who suppress virus replication to levels below the
limit of detection of standard assays, low-level ongoing replication
can be detected through the analysis of the HIV-1 episomes.
Therefore, in highly suppressed individuals who have undetectable
virus in plasma, analysis via episomal HIV-1 cDNA provides the
means to monitor and define the nature of actively replicating
virus that persists in the face of ART.
Here we have focused on analyzing episomal envelope (env)
sequences to probe the nature of actively replicating virus that
persists during ART and demonstrate the utility of episomal
sequence analysis in guiding clinical treatment of infected
individuals. Envelope sequences were compared to define the
phylogenetic relationships between episomal and proviral genomes
prior to rebound in patients on ART to RNA genomes of virus
that emerged upon therapy interruption. Additionally, episomal
env genes were analyzed from a group of patients undergoing
salvage therapy with Vicriviroc (VCV) in order to predict the
virologic response to this CCR5 antagonist.
Results
Phylogenetic analysis of rebounding virus
Several approaches have been used in previous studies to
attempt to characterize the virus that fuels the rapid rebound of
viremia upon interruption of ART with conflicting results [18–21].
To address this issue, we compared rebound virus env sequences to
episomal and proviral env sequences that were present immediately
prior to treatment interruption in a group of six individuals. The
rationale for this analysis is that episomal HIV-1 genomes are a
dynamic marker for recent infections and are representative of a
reservoir in which HIV-1 is actively replicating, while proviral
genomes are predominantly archival and defective [22,23].
Peripheral blood lymphocytes and plasma were obtained for a
group of patients who had plasma viral RNA measurements below
the level of detection for a minimum of 20 months (Fig 1).
Episomal env sequences could not be amplified from four of the
original set of patient samples and were excluded from the
analysis. During the treatment period, patients suppressed viral
replication with a combination of two nRTIs and at least one
protease inhibitor (Table1). It should be noted that apparent
increases in plasma viral RNA resulted from the use of assays with
different limits of detection (,50 or ,500 HIV-1 RNA copies per
ml) and not from transient increases in viral replication. Upon
therapy interruption, HIV-1 replication, based on plasma viral
RNA measurements, rapidly resurged in all patients (Fig 1). DNA
from peripheral blood lymphocytes was purified to selectively
enrich for chromosomal and extrachromosomal fractions and the
C2 to V4 regions of env were amplified by nested PCR using
episomal-specific or proviral-specific primer pairs (Fig 2). Using
this fractionation step greatly increases the likelihood that only the
intended target DNA is amplified. The majority of unintegrated
HIV-1 genomes remain in the supernatant and only a small
amount of chromosomal DNA, potentially harboring an integrat-
ed provirus, partitions to the extrachromosomal fraction. De-
pending on the number of proviruses in a given sample, the level
of contamination ranges from about 1 to 2 percent (Fig S1). Since
the proviral frequency in patients on HAART is low [11,24],
amplifying env from a proviral template in the extrachromosomal
fraction is unlikely.
In order to promote phylogenetic comparison between baseline
and rebounding viral genomes, plasma virus was sampled shortly
after viral rebound. This minimized sequence diversity that
develops during uncontrolled virus replication at therapy inter-
ruption. Env sequences from plasma virions collected from plasma
sampled shortly after rebound were generated by RT-PCR.
Nucleotide sequences were aligned using ClustalW (MacVector
8.1) and neighbor-joining phylogenetic trees were constructed
using the Kimura two-parameter model as implemented in the
MEGA Version 4 program [25]. Confidence values for individual
branches using 1000 replicates were estimated by bootstrap re-
sampling of the neighbor-joining trees (Fig 1). Since the initial
phylogenetic analyses may have included sequences based on PCR
re-sampling, redundant sequences were removed from the
alignments and best trees were generated using MacVector 8.1
to demonstrate data consistency and calculate genetic distances for
different sequences (Figs S2–S7). All patient sequences were
aligned to each other and in each case the patient sequences
clustered with one another, but not with sequences from other
patients or reference lab strains. In the majority of patients, env
Author Summary
Infection by HIV-1 and the related effects on human health
continue to be a major problem throughout the world.
Since the early 1980’s, more than 25 million people have
died from AIDS and the only treatment option for infected
individuals is likely to be life-long treatment with a
combination of antiviral drugs. While antiviral drug therapy
can reduce viral replication to levels that are undetectable
by currently used assays, there is a rapid recrudescence of
viremia upon interruption of therapy. This indicates that
there are viral reservoirs, undetectable by conventional
diagnostic assays that sustain the virus in the face of ART.
We have developed an alternative or additional approach
to study cryptic viral replication based on episomal HIV-1
genomes. Although HIV-1 episomes are not suitable
substrates for integration and thus are dead-end products
in the viral life cycle, episomal HIV-1 genomes are useful
surrogate markers of viral replication since they are labile
and indicative of recent infection events. Here we have
used episomal HIV-1 analysis to study the reservoir that
fuels viral rebound during treatment interruption and to
demonstrate the utility of this approach in guiding the
clinical treatment of infected individuals.
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sequences present just prior to treatment interruption, but not to
proviral sequences obtained from the same sampling time (Fig 1,
Figs S2–S7). In some patients, there was tight intermingling of
rebound RNA and episomal sequences demonstrating very close
genetic similarity supporting the conclusion that viral rebound
originated from a reservoir in which viral replication was ongoing
(Fig 1, Figs S2–S4).
Table 1. Profiles of the HIV-1-infected patients.
PVL* TCD4
Patient ID Date Time point (copies/ml) (cells/ml) Antiretroviral regimen
Patient 1 06/12/97 220 mo. ,500 1408 3TC d4T NFV SQV
01/22/98 212 mo. ,50 1101 3TC d4T NFV SQV
07/14/98 26 mo. ,50 1289 3TC d4T NFV SQV
12/16/98 21 mo. ,50 863 3TC d4T NFV SQV
01/06/99 Off therapy 0 wk ,50 1078 none
03/05/99 Off therapy 8 wks 11466 792 none
Patient 2 10/08/96 230 mo. ,50 1173 3TC d4T IDV
03/04/97 224 mo. ,50 1147 3TC d4T IDV
07/23/97 219 mo. ,500 1066 3TC d4T IDV
01/12/98 213 mo. ,50 832 3TC d4T IDV
07/07/98 27 mo. ,500 1146 3TC d4T IDV
12/22/98 21 mo. ,50 1200 3TC d4T IDV
01/13/99 Off therapy 0 wk ,50 1021 none
02/09/99 Off therapy 4 wks 7834 832 none
Patient 3 09/25/97 223 mo. ,50 765 3TC d4T IDV
01/15/98 219 mo. ,50 962 3TC d4T IDV
07/29/98 212 mo. ,50 825 3TC d4T IDV
11/18/98 28 mo. ,50 852 3TC d4T IDV
06/02/99 21 mo. ,50 781 3TC d4T IDV
06/29/99 Off therapy 0 wk ,50 767 none
07/22/99 Off therapy 3 wks 67033 554 none
Patient 4 04/23/97 225 mo. ,50 2220 3TC AZT IDV
10/08/97 219 mo. ,50 1518 3TC AZT IDV
03/25/98 213 mo. ,50 1454 3TC AZT IDV
09/09/98 27 mo. ,50 1663 3TC AZT IDV
02/24/99 21 mo. ,50 1244 3TC AZT IDV
03/23/99 Off therapy 0 wk ,50 1740 none
04/12/99 Off therapy 3 wks 170191 1101 none
Patient 5 04/16/97 225 mo. ,500 2244 3TC d4T
11/24/97 217 mo. ,50 2093 3TC d4T
03/16/98 213 mo. ,500 1863 3TC d4T IDV
8/31/98 27 mo. ,50 2106 3TC d4T IDV
02/16/99 21 mo. ,50 1819 3TC d4T IDV
03/09/99 Off therapy 0 wk ,50 1720 none
04/05/99 Off therapy 4 wks 44235 1368 none
Patient 6 03/31/97 224 mo. ,500 1550 3TC d4T IDV
10/15/97 217 mo. ,50 1187 3TC d4T AZT IDV
03/30/98 211 mo. ,50 1012 3TC AZT IDV
07/28/98 27 mo. ,500 1149 3TC AZT IDV
01/04/99 21 mo. ,50 1138 3TC AZT IDV
01/26/99 Off therapy 0 wk ,50 1117 none
02/23/99 Off therapy 4 wks 10684 892 none
PVL, plasma viral load; TCD4, total CD4 cells; 3TC, lamivudine; d4T, stavudine; AZT, zidovudine; NFV, nelfinavir; SQV, saquinavir; IDV, indinavir.
*Plasma viral loads were measured using assays that have a limit of detection of either 50 or 500 copies/ml.
doi:10.1371/journal.ppat.1001303.t001
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PLoS Pathogens | www.plospathogens.org 4 February 2011 | Volume 7 | Issue 2 | e1001303Figure 1. Phylogenetic trees based on the C2-V4 regions of envelope for six different patients undergoing interruption of antiviral
treatment. Plasma viral RNA copies (either 500 or 50 copies/ml detection limit) and CD4
+ T cell percentages are shown for patients prior to and after
suspension of ART. In all patients, there was a rapid rebound of plasma viral RNA when therapy was discontinued. Phylogenetic relationships were
estimated using the neighbor-joining method for episomal (yellow triangle) and proviral (blue circle) envelope sequences derived at therapy
interruption to plasma viral RNA (orange square) envelope sequences obtained several weeks after rebound. Each symbol represents an individual
sequence analyzed. Envelope sequences from HIV-1LAI and HIV-1ADA laboratory strains (black stars) are included for reference. Numbers at branch
nodes refer to the bootstrap support; only frequencies greater than 70 percent are shown.
doi:10.1371/journal.ppat.1001303.g001
Figure 2. Strategy for long-range PCR amplification of episomal or proviral HIV-1 envelope sequences. Major cDNA intermediates in
reverse transcription are denoted. Thin blue line, viral RNA; thick blue line, cDNA. Primer-binding sites for initiation of minus-strand cDNA synthesis
and polypurine tracks for plus- or minus-strand synthesis are indicated by open circles and squares, respectively. Relative positions and orientations
of first and second round PCR primers specific for the different forms of HIV-1 are listed.
doi:10.1371/journal.ppat.1001303.g002
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Phylogenetic analysis of viral env sequences in individuals who
interrupted therapy indicated that plasma viremia originated from
a cryptic viral reservoir as identified by episomal sequences (Fig 1).
However, it is possible that the viral variants identified by episomal
sequences were of limited biological relevance to the immuno-
pathogenic status of the host. To evaluate whether the cryptic viral
reservoir that is revealed by episomal viral cDNA was of virologic
relevance, we examined whether episomal sequences define a viral
population that contributes to the virologic outcome of individuals
receiving co-receptor inhibitors. HIV-1 infected individuals most
frequently fail CCR5 inhibitor therapy because of the presence of
a low frequency of X4 virus variants that are insensitive to CCR5
antagonists. Therefore, we hypothesized that identification of X4
viruses based on V3 env sequences in episomal cDNA would
predict treatment failure. From ACTG trial 5211 in which patients
received the CCR5 antagonist Vicriviroc (VCV), we selected
fourteen patients who experienced protocol-defined virologic
failure. Virologic failure for this protocol is defined as failure to
experience a log reduction in viral replication from baseline values
at or after week 16. Episomal env sequences were generated by
PCR from lymphocyte DNA isolated from baseline through week
48 after initiation of VCV therapy. Full-length env genes were
amplified from episomal cDNA and cloned into an expression
vector. Pseudotyped viruses were generated with patient-derived
envelopes and an NL4-3 proviral clone expressing luciferase in
place of envelope. Co-receptor dependence was then gauged in an
infection assay utilizing U87-based indicator cells. Amplification of
full-length env genes was problematic for a small number of
samples. Therefore, in order to derive secondary information on
virus genotypes from these samples, short fragments spanning the
V3 region of env were amplified and sequenced. Tropism
predictions were determined using the Geno2Pheno algorithm
with a false positive rate of five and ten percent as well as coupled
11/25 and net charge rules. The phenotypic/genotypic data is
summarized in Tables 2 and S1 and tropism assignments based on
an RNA phenotyping assay (Trofile, Monogram Biosciences) are
listed for comparison. We were able to amplify either full-length or
short episomal env fragments from 74 of 91 (81.3%) PBMC
samples. The Trofile assay and phenotypic assay based on
episomal env sequences were concordant at all timepoints for 8
of the 14 patients. In these individuals, R5 viruses persisted at all
time points based on both phenotypic assays and virologic failure
could not be explained by outgrowth of X4 virus (Tables 2, S1). In
the remaining 6 patient samples, tropism assignments resulted in
notable discordance. In one individual (Patient A), the Trofile
assay indicated the presence of D/M virus at all time points, while
our assay detected only CCR5-dependent virus. PBMC samples
from patients J and K showed the emergence of X4 or D/M
viruses at baseline or week 2, which was prior to assignments based
on the Trofile assay. However, co-receptor use based on re-testing
of baseline samples with an enhanced-sensitivity Trofile assay
revealed the presence of D/M viral variants in patients D, J, and
K, which is in accordance with our assay based on episomal env
sequences [26,Table S2]. Therefore, analysis of tropism from
sequences contained with env of episomal cDNA revealed the
presence of X4 variants at or near baseline and predicted virologic
failure.
Discussion
Although current antiviral treatment can successfully reduce
viral loads to undetectable levels in HIV-1 infected individuals,
viral reservoirs persist. In order to guide efforts aimed at
eradication of the virus from infected cells, it is critical to develop
a comprehensive knowledge of the viral reservoirs that are
maintained in the face of suppressive antiviral treatment. Since
well-suppressed individuals have extremely low to undetectable
levels of virus in peripheral blood, an alternative to virion RNA
analysis is needed. Detection and analysis of episomal HIV-1
genomes, in patients in which virus replication is suppressed to
levels below the limit of detection of standard assays, provides an
option to characterize virus that persists in such individuals. We
have previously shown that episomes are labile in vivo, and
therefore, are valid surrogate markers for recent infections [10].
Here we have applied episomal analysis to characterize virus
that rebounds upon antiviral treatment interruption. In an analysis
of six patients, there was a rapid rebound in plasma viral RNA
when therapy was interrupted after a prolonged period of
sustained suppression of viral replication. Phylogenetic relation-
ships based on C2 to V4 env sequences indicated that in the
majority of patients, rebounding virus was highly similar to
episomal sequences that existed prior to treatment interruption,
but were not closely related to proviral sequences present at the
same sampling time. As such, HIV-1 episomal cDNA is
representative of a relevant biological reservoir that persists in
individuals on ART and whose characteristics may not be defined
by other assays. We observed considerable variability in the
diversity of episomal sequences derived from the different patients.
In patients on HAART, episomal HIV-1 genomes are rare and
inter-patient variability can be high. We have previously observed
that 2-LTR HIV-1 quantities in patients receiving highly
suppressive antiviral therapy range from less than one to greater
than 600 copies per million PBMCs [7]. In this study, env sequence
diversity was dependant on the relative abundance of episomal
genomes present in the samples (data not shown).
Previous studies aimed at revealing the origin of virus that
rebounds upon therapy interruption have reached different
conclusions. Both activation of latently infected CD4
+ T cells
and low-level active viral replication have been implicated in the
rapid resurgence of viremia following treatment interruption [18–
21,27]. Our analysis provides additional in vivo evidence that
residual viral replication persists in patients on highly suppressive
therapies and that viral rebound is fueled by this cryptic
replication. While the present study supports the hypothesis that
HIV-1 rebounds from a reservoir in which replication is ongoing,
a recent study by Joos et al. concluded that rebounding virus is
derived from the activation of latently infected cells [27]. The
conclusion is based upon comparisons of residual viremia and
virus that rebounds upon multiple treatment interruptions.
Although the data is consistent with activation from latently
infected cells, analysis of proviruses was not included, so one
cannot be certain of the source of rebounding virus. Here we have
directly compared proviruses and episomes to rebounding virus
and conclude that it is more likely that the rebounding virus is
derived from actively replicating virus. Work by others has
suggested that at least some of the plasma virions that are
produced in the setting of ART harbor replication competent virus
[28]. Although this suggests that residual viremia can fuel HIV-1
rebound upon therapy interruption, the study was done with a
single patient, so it is difficult to generalize the findings.
Phylogenetic analysis of tat sequences derived from plasma virions
and CD4
+ T cells from the same patient revealed that most
sequences generated from plasma were distinct from those in
CD4
+ T cells, which is consistent with previous studies [29–31].
These studies have concluded that residual viremia is derived from
a source other than CD4
+ T cells. Our analysis focused on
genomes that were associated with PBLs, and given the genetic
HIV-1 Episomes and Viral Rebound
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Patient ID and time point
(# of clones) log 10 HIV-1 RNA copies/ml
Amplification of env gene
from episomes
Phenotype Genotype*
(episomal cDNA)
Trofile assay (plasma viral
RNA)
Patient A
baseline 4.6 no sample - DM
week 2 (5) 3.8 full-length R5 DM
week 4 (3) 4.5 V3 R5* -
week 8 (4) 4.1 full-length R5 DM
week 16 (4) 4.2 full-length R5 -
week 24 (5) 3.3 full-length R5 DM
week 48 1.2 NA - -
Patient B
a
baseline (5) 5.3 full-length R5 R5
week 2 (5) 5.8 full-length R5 R5
week 4 (5) 5.6 full-length R5* -
week 8 (5) 5.5 full-length R5 R5
week 16 (5) 4.7 full-length R5 -
week 24 (5) 5.2 full-length R5 R5
week 48 (1) 6.5 full-length R5* R5
Patient D
baseline 5.6 no sample - R5
week 2 (5) 6.2 full-length D R5
week 4 (5) 5.5 full-length D -
week 8 (5) 5.0 full-length R5 R5
week 16 (5) 4.6 full-length R5 -
week 24 (1) 4.6 full-length R5 -
week 46 (5) 4.1 full-length D R5
Patient G
baseline 5.2 no sample - R5
week 2 4.9 NA - R5
week 4 4.6 NA - -
week 8 (2) 5.2 full-length X4 R5 DM
week 16 (5) 4.3 V3 R5* -
week 48 (3) 5.1 full-length R5* DM
Patient J
baseline (5) 4.5 full-length X4 R5
week 2 (4) 4.6 full-length X4 R5 R5
week 4 (3) 4.3 full-length X4 -
week 8 (2) 4.2 full-length X4 R5 X4
week 16 (1) 4.3 full-length X4 -
week 24 4.5 NA - DM
week 48 5.1 NA - DM
Patient K
baseline 4.5 no sample - R5
week 2 (5) 4.2 full-length D R5 R5
week 4 (5) 4.6 full-length R5 -
week 8 (4) 4.5 full-length D R5 R5
week 16 (5) 4.2 V3 X4 R5* -
week 26 (5) 4.6 V3 X4 R5* -
week 48 (4) 4.4 V3 R5* DM
Patient L
baseline 4.6 no sample - DM
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genomes may be derived from a reservoir that is distinct from
the source of residual viremia. Although it would be potentially
informative to compare env sequences that we generated to env
present in patient plasma prior to rebound, it was not possible due
to the archival nature of our samples. Additionally, one might
predict that the sources of residual viremia and episomes are
distinct based on the results of therapy intensification with
raltegravir in which episomes increase transiently [13,15] while
residual viremia remains unchanged [16,17]. Evidently, more
work is needed to better define the viral reservoirs that persist
despite highly suppressive ART.
To further support the methodology and demonstrate that
episomal analysis has the potential to provide information with
which to guide clinical decisions regarding patient therapy, we
analyzed samples from individuals undergoing salvage treatment
with the CCR5 antagonist VCV. Although these patients had
varying levels of viremia, we wanted to determine whether
episomal HIV-1 cDNA analysis could provide information on the
effects of adding VCV to a regimen that was no longer effective in
suppressing viral replication. We were able to generate full-length
env genes from sixty-four percent of the samples and of the samples
in which viral plasma RNA copies were below 100, we could
amplify env fifty percent of the time. Thus, targeting episomal
genomes provides a feasible approach to the study of residual virus
replication.
Although VCV is considered to be a potent inhibitor of R5
HIV-1 in vitro and in vivo [32,33], the patients we focused on
exhibited a poor response to therapy as defined by the clinical
protocol. In five patients, phenotypic or genotypic analysis of
episomal env genes indicated the presence of dual or X4 viruses
while undergoing therapy. For these patients, it is highly likely that
failure to respond to VCV therapy was due to the presence of viral
variants that were unaffected by the CCR5 antagonist. In all cases,
D/M or X4 viruses were present at early time points of the trial, so
it is unlikely that selective pressure from VCV therapy resulted in a
replacement of R5 with X4 virus. We observed very little
variability in the primary V3 loop sequences of the patient
samples, so the basis for VCV therapy failure is unclear in the
subset of patients that did not harbor X4 or D/M viruses. These
results are consistent with previous work studying the same group
of patients [34] and imply that resistance to the antagonist may
involve env sequences that are peripheral to the V3 loop or involve
other, as yet undefined determinants. Alternatively, patients who
experienced virologic failure with R5 virus may not have been
fully compliant with the regimen.
Since most of the samples were analyzed while patients were
experiencing viremic episodes, we were able to compare our assay
data to phenotypic data previously obtained via the Trofile assay
[33]. Trofile is a single-cycle recombinant virus assay in which
pseudoviruses are generated from full-length RNA-derived env
genes to determine HIV-1 tropism from plasma virions [35]. This
assay is the current ‘‘gold standard’’ to determine viral tropism and
to guide whether CCR5 antagonists should be considered in the
clinical management of an infected individual. Clinicians need
tropism determinations to exclude the possibility that CCR5
antagonist use will result in outgrowth of a more pathogenic virus
utilizing the CXCR4 co-receptor. However, a significant limita-
tion to the assay is the requirement that viral plasma RNA levels
be greater than 1000 copies/ml [35]. The Trofile assay and
phenotypic assay based on episomal env sequences were highly
concordant. The high degree of correlation between the two assays
indicates that episomes are not archival, but are evolving and
derived from a reservoir of actively replicating virus. While the
majority of samples analyzed were from time points in which viral
plasma RNA was greater than the limit of detection, we would
expect episomal analysis to be a viable approach in patients that
suppress virus replication to levels below the limit of detection of
standard assays. Having a method to determine viral co-receptor
usage in patients with highly suppressed viremia would be
advantageous for patient management. It is common for patients
to experience toxicity from the drug regimens in use and defining
the virus co-receptor dependence would allow a clinician to switch
therapy to a better tolerated drug such as a CCR5 antagonist.
Previous studies have shown that 2- LTR episomes are
detectable in a high percentage of patients on long-term highly
suppressive antiviral therapy [7,13]. Additionally, the approach we
used to amplify env from episomes also targets 1-LTR circles that
are approximately ten times more abundant than 2-LTR circles
resulting in a much greater sensitivity of detection [36]. Taken
together, the results support the use of episomal HIV-1 cDNA as
an additional or alternative approach to traditional assays to
monitor the effects of antiviral therapy, and to help guide decisions
on which patients may be most responsive to co-receptor inhibitor
therapy, even for patients in which viremia is undetectable based
on standard assays.
Materials and Methods
Ethics statement
After obtaining written informed consent, cells and plasma were
collected by phlebotomy from HIV-1 infected volunteers at the
Patient ID and time point
(# of clones) log 10 HIV-1 RNA copies/ml
Amplification of env gene
from episomes
Phenotype Genotype*
(episomal cDNA)
Trofile assay (plasma viral
RNA)
week 2 (5) 5.0 full-length D R5 R5
week 4 (1) 5.5 full-length R5 -
week 8 (2) 5.8 full-length X4 R5* R5
week 16 (5) 5.5 V3 R5* -
week 48 1.2 NA - -
NA, no amplification of full-length or short env fragment; DM, dual/mixed; D, dual-tropic virus.
*If amplification of the full-length env gene was not successful or if the phenotypic assay failed, secondary information on the virus genotype was derived by amplifying
and sequencing a short fragment spanning the V3 region of env.
aSeven more patients with concordant results between the two assays are presented in Table S1.
doi:10.1371/journal.ppat.1001303.t002
Table 2. Cont
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Group (ACTG) protocol A5211. Eligible participants were age 18
or older and either voluntarily suspended ART or chose to receive
a new antiviral compound in the context of salvage therapy. The
study was reviewed and approved by both the NIAID and the
University of Massachusetts’s institutional review boards. Human
experimentation guidelines of the US Department of Health and
Human Services were followed in the conduct of this research.
Rebound study
Patients. Six HIV-1 infected individuals who were receiving
effective antiviral treatment for approximately 2 years and
subsequently suspended therapy were studied. None of the
patients exhibited any detectable viremia prior to suspension of
therapy, based on plasma viral RNA measurements (limit of
detection 50 or 500 copies per milliliter). PBMCs were obtained
prior to, and at the time of, therapy interruption via leukapheresis
by Ficoll-Hypaque density gradient centrifugation. One milliliter
of plasma was obtained 3, 4 or 8 weeks after suspension of therapy
at which time viral rebound had occurred. The study was
approved by the NIAID’s institutional review board and informed
consent was obtained in writing from study participants. Human
experimentation guidelines of the US Department of Health and
Human Services were followed in the conduct of this research.
DNA and RNA purifications. Low molecular weight DNA
was purified using a modified plasmid isolation procedure (Qiagen)
and chromosomal DNA was subsequently recovered from the
SDS-precipitate by extraction with DNazol (Invitrogen).
Cryopreserved PBMCs were collected by centrifugation at 4
KRPM for 5 min and DNA was purified according to the
manufacturer’s modified plasmid protocol for low copy number
samples. SDS-precipitates were then thoroughly resuspended in
900 mL DNazol at 50uC and DNA was precipitated by the
addition of 500 mL 100% ethanol. DNA was pelleted by
centrifugation at 12 KRPM for 8 min, washed in 1.4 ml 70%
ethanol and resuspended in 50 mL 8 mM NaOH. After
resuspension, lysates were neutralized by the addition of 50 mL
10 mM Tris-HCl, pH 8.0. Virions were pelleted from thawed
plasma at 14 KRPM for 2 h at 4uC and RNA was purified using
an RNAeasy kit according to the manufacturer’s protocol (Qiagen)
and eluted in 50 mL water.
Amplification and sequencing of env genes. A portion of
the envelope gene spanning the C2 to V4 region was amplified by
nested PCR using limiting dilution replicates of the first round
products. First round products were generated using episomal-
specific (LA16/f, T
5905GGGTCACAGTCTATTATGGGGTA
and LA17/r, T
332CTCCTTCTAGCCTCCGCTAGTCAA) or
proviral-specific primers (Alu/f, CTCACGCCTGTAATCC-
CAGCA or Alu/r, TGCTGGGATTACAGGCGTGAG) and
LA9/f, A
6015CATGCCTGTGTACCCACAGA) and Jumpstart
RedAccuTaq (Sigma) in a reaction containing 1X buffer, 250 mM
dNTPs, 0.5 mM primers and 1.5 units polymerase. PCR
conditions consisted of a denaturation step at 95uC for 1 min
followed by 22 cycles of 15 sec at 95uC, 30 sec at 58uC and 5 min
at 68uC. Second round products were generated using 40 cycles of
amplification as above except with an extension time of 1 min and
LA11/f (C
6546ACAGTACAATGTACACATGGA) and Env7/r
(A
7128GGGGCATACATTGCTTTTCCTA) envelope primers.
8 mL viral RNA was converted to cDNA using Superscript RT
(Invitrogen) according to the manufacturer’s protocol. cDNA was
amplified by limiting dilution pcr using the same conditions as the
second round reactions above. PCR products were purified and
used directly for sequencing with the LA11/f primer. Primers were
numbered according to the HIV-1LAI consensus (K02013).
Phylogenetic analysis. Nucleotide sequences corresponding to
t h eC 2t oV 4r e g i o n so fenv were edited and aligned using ClustalW
(MacVector 8.1) and phylogenetic relationships were generated using
the neighbor-joining method included in the MEGA 4 software
package with a Kimura-2 parameters distance matrix. Confidence
limits for individual branches were estimated by bootstrap re-
sampling of the neighbor-joining trees (1000 replicates).
Co-receptor study
Patients and samples. The study was conducted using
archival patient samples that had originally been collected under
AIDS Clinical Trials Group (ACTG) protocol A5211, a phase 2b
study of the investigational CCR5 antagonist Vicriviroc (VCV).
The study was approved by the University of Massachusetts’s
institutional review board and informed consent was obtained in
writing from study participants. Human experimentation
guidelines of the US Department of Health and Human
Services were followed in the conduct of this research. Ninety-
one cryopreserved PBMCs were obtained from fourteen HIV-1-
infected, treatment-experienced patients, who experienced
protocol-defined virologic failure. PBMCs were collected during
the period from study entry through week 48 (week 0, 2, 4, 8, 16,
24 and 48). PBMCs at study entry (week 0) were available only for
six out of fourteen patients.
DNA purifications. Nucleic acid extractions were performed
from patients’ cryopreserved PBMCs samples (5610
6 cells).
PBMCs were collected by centrifugation at 4 KRPM for 5 min.
Cell pellets were resuspended in buffer P1 and extrachromosomal
DNA was purified using a QIAprep spin miniprep kit (Qiagen)
using the modification for the isolation of low copy number
plasmids as recommended by the manufacturer. Final elution of
the purified DNA was in 120 ml of elution buffer preheated at
70uC.
Amplification and cloning of full-length envelopes. HIV-
1 full-length env sequences within episomal DNA (1- and 2-LTR)
were amplified from 20–30 ml of extrachromosomal DNA by
nested PCR using the Phusion Hot Start High-Fidelity DNA
Polymerase (Finnzymes, Espoo, Finland). Amplifications were
done in a 50-ml reaction containing 1 x Phusion HF Buffer,
200 mM deoxynucleotide triphosphates, 0.5 mM primers, and 1 U
of Phusion Hot Start DNA Polymerase. Outer primers were envA
(forward, T
5434AGAGCCCTGGAAGCATCCAGGAAG) and
LA17 (reverse, T
332CTCCTTCTAGCCTCCGCTAGTCAA),
and inner primers were envB (forward, CACCT
5539AGGCAT-
CTCCTATGGCAGGA) and envM (reverse, C
8501CAGGTCT-
CGAGATGCTGCTCCCA). Primers were numbered according
to the HIV-1LAI consensus (K02013).
After an initial denaturation at 98uC for 1 min, first round
products were generated by cycling 25 times at 98uC for 15 s,
60uC for 30 s, and 72uC for 3.30 min, followed by a final
extension at 72uC for 5 min. Two microliters from the first round
were then used for nested PCR which was performed with an
initial denaturation step of 98uC for 1 min, followed by 25–30
cycles of 98uC for 15 s, 63uC for 30 s, and 72uC for 1.45 min, and
a final extension of 72uC for 5 min.
PCR product DNA was purified over a column using QIAquick
PCR Product Purification Kit (Qiagen) and cloned into the
pcDNA3.1D/V5-His-TOPO expression vector (pcDNA3.1 Direc-
tional TOPO Expression Kit, Invitrogen). Plasmids were isolated
with Qiagen miniprep purification kit (Qiagen) and were digested
with HindIII and XhoI to confirm insertion of full-length env.
Amplification and cloning of partial env sequences. Short
env fragment, encompassing V3 region was amplified within
episomal cDNA by nested PCR using envA/LA17 as outer
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6602 TGGCAGTCTAGCAGAAG-
AAGA) and LA13 (reverse, T
6927 TCTGGGTCCCCTCC-
TGAGGA) as inner primers. The PCR products were subjected
to clonal analysis using StrataClone Blunt PCR Cloning Kit
(Stratagene).
Genotypic characterization of HIV-1 co-receptor
usage. The V3 region was sequenced from cloned env with
LA12 primer using an ABI/Prism 377 DNA sequencer (Applied
Biosystems). Sequences were edited and aligned with MacVector
software (v.10.0.2). To predict HIV-1 tropism from the V3
genotype we used bioinformatic tool Geno2pheno (http://
coreceptor.bioinf.mpi-sb.mpg.de/cgi-bin/coreceptor.pl) with a
false positive rate of 5% and 10%, as well as, coupled 11/25
and net charge rules.
Phenotypic characterization of HIV-1 co-receptor
usage. The phenotype of HIV-1 co-receptor usage was
determined using a single-cycle recombinant virus entry assay.
Human embryonic kidney 293T cells were co-transfected using
Lipofectamine 2000 (Invitrogen) with pNL43-Denv-Luc vector
DNA and expressing vector containing the amplified full-length env
sequence. Virus particles released into the supernatant after
48 hours were used to infect indicator cells bearing CD4 and
CCR5 (U87.CD4.CCR5 cells) or CD4 and CXCR4
(U87.CD4.CXCR4 cells) (these reagents were obtained through
the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH). Recombinant viruses with
known co-receptor usage (X4 LAI, R5 LAI and D/M 89.6 virus)
were used as controls in each assay. 293T cells transfected with
empty vector plasmid were used as negative control. The ability of
pseudoviruses to infect target cells was assessed by measuring the
luciferase activity in lysed cells (as relative light units; RLU) 72 h
postinoculation with Bright-Glo Luciferase Assay System
(Promega). Tested virus was assigned a particular tropism if
infection of cells expressing the relevant co-receptor resulted in an
RLU reading above the background. The specificity of low-level
positive luminescent signals was confirmed using co-receptor
antagonists. Bicyclam JM-2987 (hydrobromide salt of AMD-3100)
was used to block CXCR4-mediated entry and TAK-779 to block
CCR5-mediated entry (these reagents were obtained through the
NIH AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH). We used three concentrations (1:3
dilutions) for each component, starting at 1.25 mg/ml for AMD-
3100 and 1.5 mg/ml for TAK-779.
Supporting Information
Figure S1 Fractionation of PBL DNA results in minimal
proviral contamination of extrachromosomal supernatants. Var-
iable numbers of 8E5 cells, which have a single HIV-1 LAI provirus
per cell, were combined with a constant 8610
6 uninfected PBLs.
DNA was purified as is described in the methods section and
quantitative PCR was used to measure the number of proviruses
that partitioned to the extrachromosomal fraction.
Found at: doi:10.1371/journal.ppat.1001303.s001 (3.00 MB TIF)
Figure S2 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 1 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma viral
RNA (orange square) envelope sequences obtained several weeks
after rebound. Envelope sequences from HIV-1LAI and HIV-1ADA
laboratory strains (black stars) are included for reference.
Found at: doi:10.1371/journal.ppat.1001303.s002 (0.21 MB TIF)
Figure S3 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 2 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma
viral RNA (orange square) envelope sequences obtained several
weeks after rebound. Envelope sequences from HIV-1LAI and
HIV-1ADA laboratory strains (black stars) are included for
reference.
Found at: doi:10.1371/journal.ppat.1001303.s003 (0.32 MB TIF)
Figure S4 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 3 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma
viral RNA (orange square) envelope sequences obtained several
weeks after rebound. Envelope sequences from HIV-1LAI and
HIV-1ADA laboratory strains (black stars) are included for
reference.
Found at: doi:10.1371/journal.ppat.1001303.s004 (0.34 MB TIF)
Figure S5 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 4 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma viral
RNA (orange square) envelope sequences obtained several weeks
after rebound. Envelope sequences from HIV-1LAI and HIV-1ADA
laboratory strains (black stars) are included for reference.
Found at: doi:10.1371/journal.ppat.1001303.s005 (0.31 MB TIF)
Figure S6 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 5 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma viral
RNA (orange square) envelope sequences obtained several weeks
after rebound. Envelope sequences from HIV-1LAI and HIV-1ADA
laboratory strains (black stars) are included for reference.
Found at: doi:10.1371/journal.ppat.1001303.s006 (0.21 MB TIF)
Figure S7 Phylogenetic tree based on the C2-V4 regions of
envelope for patient 6 undergoing interruption of antiviral
treatment. Phylogenetic relationships were estimated using the
neighbor-joining method to generate best tree with genetic
distances for episomal (yellow triangle) and proviral (blue circle)
envelope sequences derived at therapy interruption to plasma viral
RNA (orange square) envelope sequences obtained several weeks
after rebound. Envelope sequences from HIV-1LAI and HIV-1ADA
laboratory strains (black stars) are included for reference.
Found at: doi:10.1371/journal.ppat.1001303.s007 (0.26 MB TIF)
Table S1 Tropism assignments based on HIV-1 env sequences
derived from episomal cDNA and plasma viral RNA from patients
with concordant results between the two assays.
Found at: doi:10.1371/journal.ppat.1001303.s008 (0.08 MB
DOC)
Table S2 Co-receptor use at baseline as determined by the
enhanced-sensitivity Trofile assay.
Found at: doi:10.1371/journal.ppat.1001303.s009 (0.04 MB
DOC)
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